Hester Bios
Hester Bios Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #80 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
1 of 3 strong
The short version
Hester Biosciences aims for holistic disease prevention by combining vaccines with biosecurity, hygiene, and health products, enhancing cross-selling opportunities, particularly in poultry. Revenue growth driven by deeper market penetration in poultry healthcare and expansion of poultry health products portfolio.
From Hester Bios's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Hester Biosciences aims for holistic disease prevention by combining vaccines with biosecurity, hygiene, and health products, enhancing cross-selling opportunities, particularly in poultry.
- Poultry segment growth driven by deeper market penetration, scientific field engagement, and expanded health product portfolio; higher market share contributing to revenue increase.
- Animal vaccine business relies on planned preventive vaccination schedules rather than outbreak-driven sudden demand; government immunization programs expected to support steady demand.
- Africa and Nepal markets hold significant growth potential, especially with local manufacturing facilities; Africa considered a promising but volatile new territory.
- Capacity utilization around 60-65% with recent addition of fill-and-finish and BSL3 facilities, indicating room for growth without immediate new capacity.
2 more points from Hester Bios's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Hester Bios said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Recent capital expenditure includes the commissioning of a new BSL3 facility and fill-and-finish capacity, with fixed assets increasing by around Rs. 200 crore in FY'26.
- The BSL3 facility, initially built for human vaccine efforts, is now being repurposed to support veterinary product manufacturing.
- Current capacity utilization is around 60-65%, including the new facilities, with efforts ongoing to optimize manufacturing output.
- Focus remains on maximizing existing manufacturing infrastructure.
2 more points from Hester Bios's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Hester Bios said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Hester Bios's call on order book
Create a free account to keep reading this call
Hester Bios — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹100 Cr, net profit ₹17 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Hester Bios's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Hester Bios and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Hester Bios Q1 FY27 results?
Hester Biosciences aims for holistic disease prevention by combining vaccines with biosecurity, hygiene, and health products, enhancing cross-selling opportunities, particularly in poultry. Revenue growth driven by deeper market penetration in poultry healthcare and expansion of poultry health products portfolio.
What is Hester Bios share price analysis?
Hester Bios currently shows a below-average growth signal. The stock trades at a P/E of 37.9 with a market cap of ₹2,014 Cr. Investors should review the full earnings analysis for detailed insights.
Is Hester Bios planning capital expenditure?
Recent capital expenditure includes the commissioning of a new BSL3 facility and fill-and-finish capacity, with fixed assets increasing by around Rs.
Keep Hester Bios on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.